A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11 years.
Rivista: The Journal of dermatological treatment
Anno: 2023
Autori: Patruno Cataldo, Fabbrocini Gabriella, Lauletta Giuseppe, Boccaletti Valeria, Colonna Cristiana, Cavalli Riccardo, Neri Iria, Ortoncelli Michela, Schena Donatella, Stingeni Luca, Hansel Katharina, Piccolo Vincenzo, Di Brizzi Veronica, Potenza Concetta, Tolino Ersilia, Bianchi Luca, Manti Sara, De Pasquale Rocco, Di Lernia Vito, Caminiti Lucia, Galli Elena, Coppo Paola, Chiricozzi Andrea, De Simone Clara, Guerriero Cristina, Amoruso Fabrizio Giuseppe, Provenzano Eugenio, Leonardi Salvatore, Licari Amelia, Marseglia Gian Luigi, Palermo Antonino, Di Pillo Sabrina, Russo Daniele, Moschese Viviana, Patella Vincenzo, Peduto Tiziana, Ferreli Caterina, Zangari Paola, Veronese Federica, Berti Samantha Federica, Gruber Michaela, Pezzolo Elena, Termine Stefania, Satta Rosanna, Dragoni Federica, Esposito Maria, Fargnoli Maria Concetta, Chiodini Paolo, Vallone Ylenia, di Vico Francesca, Picone Vincenzo, Napolitano Maddalena
DOI: 10.1080/09546634.2023.2246602
PubMed: Visualizza su PubMed
Abstract
Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months to 11 years in randomized clinical trials. Aim: The aim of this real-life study was to determine the effectiveness in disease control and safety of dupilumab at W52 in moderate-to-severe AD children aged 6-11 years. All data were collected from 36 Italian dermatological or paediatric referral centres. Dupilumab was administered at label dosage with an induction dose of 300 mg on day 1 (D1), followed by 300 mg on D15 and 300 mg every 4 weeks (Q4W). Treatment effect was determined as overall disease severity, using EASI, P-NRS, S-NRS and c-DLQI at baseline, W16, W24, and W52. Ninety-six AD children diagnosed with moderate-to-severe AD and treated with dupilumab were enrolled. Ninety-one (94.8%) patients completed the 52-week treatment period and were included in the study. A significant improvement in EASI score, P-NRS, S-NRS and c-DLQI was observed from baseline to weeks 16, 24 and 52. Our real-life data seem to confirm dupilumab effectiveness and safety in paediatric patients. Moreover, our experience highlighted that patients achieving clinical improvement at W16 preserved this condition over time.